{
  "ticker": "4DX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975500",
  "id": "02975500",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250731",
  "time": "1653",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mdbyfdsqbfz0.pdf",
  "summary": "### **Material Information Summary (ASX:4DX)**  \n\n- **Strategic Investment by Pro Medicus**: $10M hybrid debt/equity facility secured.  \n- **Structure**:  \n  - **Interest**: 12.5% p.a., **Maturity**: 2 years.  \n  - **Repayment**:  \n    - Cash: Higher of $12.5M **or** $10M \u00d7 (4DX VWAP at maturity / VWAP at execution), capped at $20M.  \n    - Shares: Issued if repayment exceeds $20M (formula-linked to VWAP).  \n- **Use of Funds**: Accelerate commercial pipeline and advance U.S. regulatory clearance for CT:VQ\u2122.  \n- **Key Option**: Pro Medicus may distribute 4DMedical products under standard terms.  \n\n*Omitted: Background on Pro Medicus, webinar details, operational updates.*",
  "usage": {
    "prompt_tokens": 1885,
    "completion_tokens": 192,
    "total_tokens": 2077,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T07:09:31.351622"
}